Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Maspero, Jorge
ANCHOR-1, NCT05274750 / 2021-005037-16: Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps Jul 2024 - Dec 2024 : Acceptance of regulatory submission in US for CRSwNP	Completed	3	276	Europe, Canada, Japan, US, RoW	Depemokimab (GSK3511294), Placebo	GlaxoSmithKline, GlaxoSmithKline Research & Development Limited	Nasal Polyps	07/24	08/24
MM09-SLIM, NCT05641272: Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen Extract	Not yet recruiting	2/3	90	RoW	3,000 MM09, 9,000 MM09, Placebo sublingual	Inmunotek S.L., LAT Research, Xolomon Tree S.L.	Allergic Rhinitis, Allergic Asthma, Allergic Rhinoconjunctivitis, Allergy to House Dust Mite	06/26	12/26

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Maspero, Jorge
ANCHOR-1, NCT05274750 / 2021-005037-16: Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps Jul 2024 - Dec 2024 : Acceptance of regulatory submission in US for CRSwNP	Completed	3	276	Europe, Canada, Japan, US, RoW	Depemokimab (GSK3511294), Placebo	GlaxoSmithKline, GlaxoSmithKline Research & Development Limited	Nasal Polyps	07/24	08/24
MM09-SLIM, NCT05641272: Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen Extract	Not yet recruiting	2/3	90	RoW	3,000 MM09, 9,000 MM09, Placebo sublingual	Inmunotek S.L., LAT Research, Xolomon Tree S.L.	Allergic Rhinitis, Allergic Asthma, Allergic Rhinoconjunctivitis, Allergy to House Dust Mite	06/26	12/26